SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- Patients now shop for doctors like consumers, and the bar just got higher (Medical Economics)
- AI in GI cancer care: From recognition to clinical value (ESMO)
- Could the Gut Microbiome Improve Colorectal Cancer Screening? (Technology Networks)
- DDW Expert Picks: Endoscopists’ Peripheral Gaze, Antibiotics for Cholangitis, and More (GI & Endoscopy News)
- The loopholes PE built to buy physicians are starting to crack (Becker’s Healthcare)
- Barrett Esophagus May Strike Decades Before Official Diagnosis (Medscape)
- A blood-based test for detection of advanced adenomas and colorectal cancer (DENEB): a multicentre diagnostic accuracy study (The Lancet Gastroenterology & Hepatology)
- AI can analyze your poop. Should it? (Business Insider)
